Quality of Vision in a Myopia Control Clinical Trial

Authors: 
Kenneth D Tran¹, Cameron K Postnikoff¹, Sanjeev Kasthurirangan¹, Kathryn Richdale¹
 

Affiliations:
CooperVision Inc., Pleasanton, California, United States
 

Purpose: 
With broader adoption of myopia management strategies, there is a need to characterise visual symptoms in a paediatric population. CooperVision has recently developed a Myopic Visual Performance Questionnaire – Quality (MVP-Q) to assess the frequency, severity, and level of bother related to common visual symptoms (Postnikoff AAO 2022). The current study is an analysis of interim results of visual symptoms in children using contact lenses over 1 month of daily wear.
 

Methods: 
The questionnaire was administered to 277 children (ages 8-12) in the US MiSight® 1 day Post Approval Efficacy Study. Subjects were randomised 3:1 to the treatment contact lens or a single vision control. Evaluations were administered at baseline (habitual correction), at 2 weeks and 1 month (with study lenses). Eleven visual symptoms were evaluated based on vision from the past week. Descriptive statistics were generated. Test-retest intraclass correlations (ICC) and item response distributions were conducted. 
 

Results: 
This cohort of participants was 49.8% female with an average age (+/- SD) of 10.4±1.4 years. The test-retest ICC total QoV frequency score was excellent between two-weeks and 1 month (0.86; 95%CI 0.83 to 0.89). The most frequently reported visual symptoms “Some” or “Most of the time” at baseline were glare (60%), difficulty focusing (39%) and blur (distance 30% and near 29%). At 1 month, the frequency of participants who reported these symptoms “Some” or ”Most of the time” decreased significantly (glare 23%, focusing 16%, blur 12%). Overall, most children reported never or rarely experiencing any visual symptoms.
 

Conclusion: 
Myopic children recently fitted with myopia correcting or controlling contact lenses generally report less symptoms than with their habitual correction.